Ann: Preliminary Final Report, page-57

This is from Mylan’s update on litigation in its Annual Report released this week (btw, all the  various disputes/litigations Mylan is involved in takes up 10 pages of its Annual Report. The go to comment for all litigation in which Mylan is defendant is “We believe that the claims in these lawsuits are without merit and intend to defend against them vigorously.)

The Company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses, including damages, fines and/or civil penalties, and/or criminal charges against the Company. These matters are often complex and have outcomes that are difficult to predict. The Company is also party to certain proceedings and litigation matters for which it may be entitled to indemnification under the respective sale and purchase agreements relating to the acquisitions of the former Merck Generics business, Agila, the EPD Business and branded generics business, and certain other acquisitions.

While the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend its position, the process of resolving these matters is inherently uncertain and may develop over a long period of time, and so it is not possible to predict the ultimate resolution of any such matter. It is possible that an unfavorable resolution of any of the ongoing matters or the inability or denial of Merck KGaA, Strides Arcolab, Abbott, or another indemnitor or insurer to pay an indemnified claim, could have a material effect on the Company’s business, financial condition, results of operations, cash flows and/or ordinary share price.
(pp. 160,161)

This was the opinion of the Independent Auditor in Strides Shasun’s last Annual Report

In our opinion, any unfavourable outcome with regard to the matter referred to in Note 37.1 to the consolidated financial statements (Note 37.1 refers to the Mylan purchase of Agila and subsequent notification of claims made by Mylan) resulting in outflow of resources, significantly in excess of amounts set aside in escrows stated in the said Note, may have an adverse effect on the functioning of the Group.   (p.115)